Get it on Google Play

Jazz Pharmaceuticals receives FDA approval for brain tumor treatment

August 6, 2025 3:08 PM EDT Send to a Friend
Jazz Pharmaceuticals plc (NASDAQ: JAZZ) announced that the U.S. Food and Drug Administration granted accelerated approval for Modeyso (dordaviprone) to ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login